• Anti-ROR1 Antibody (Zilovertamab) Workflows

  2026-09-14

  Build reproducible ROR1 binding, cell-surface phenotyping, and pathway-blockade assays with Anti-ROR1 Antibody (Zilovertamab). This guide also shows how to use the reagent in a carefully bounded extension of deoxynivalenol liver-injury research without confusing an exploratory bridge with validated mechanism.

• Omega-3 PUFAs Protect Against Cisplatin Nephrotoxicity

  2026-09-14

  A December 2024 study found that combined EPA and DHA reduced cisplatin-induced kidney injury more effectively than either fatty acid alone in mouse and renal tubular models. Its main mechanistic contribution is linking p62–Keap1–Nrf2 antioxidant signaling with MDM2-mediated suppression of p53-dependent apoptosis, while also examining longer-term renal fibrosis.

• Prestained Protein Marker for SepM Assay Control

  2026-09-13

  Learn how a Prestained Protein Marker can strengthen size control and transfer assessment in SepM-related protein studies. This article connects the Triple color protein ladder with the pH-dependent biochemical findings reported in Streptococcus mutans clinical isolates.

• Cy5 NHS ester(Et): Practical Labeling Guide

  2026-09-12

  Cy5 NHS ester(Et) is a water-compatible reagent for covalently labeling primary amines in proteins, peptides, and related biomolecules for fluorescence-based detection. It is suited to fresh labeling workflows, but should not be prepared in ethanol or retained as a long-term working solution.

• Gamma-linolenic acid: Applied Research Workflows

  2026-09-11

  Build more interpretable inflammation and lipid-signaling experiments with Gamma-linolenic acid (GLA), from receptor-binding studies to viability and apoptosis assay workflows. This guide connects exposure control, orthogonal readouts, and resistance-monitoring principles to practical anti-inflammatory research while highlighting formulation and stability safeguards.

• AMG 487 for Reliable CXCR3 Assays

  2026-09-11

  Learn how AMG 487 (SKU B3266) can clarify CXCR3-dependent migration, calcium signaling, macrophage polarization, and assay-related viability concerns. This scenario-based guide translates potency, solubility, storage, metabolism, and literature evidence into practical laboratory decisions.

• Predicting Netarsudil–siRNA Nanoparticle Codelivery

  2026-09-10

  Slaughter and colleagues developed a quantitative workflow that predicts whether ionizable drugs can complex siRNA and support nanoparticle encapsulation. Netarsudil was identified as a high-performing candidate and tested with CTGF-targeting siRNA in fibrotic human trabecular meshwork cells, linking formulation design with changes in gene expression and actin organization.

• Tin Mesoporphyrin IX: HO Assay Workflows

  2026-09-10

  Tin Mesoporphyrin IX (chloride) provides a direct, nanomolar-affinity tool for testing whether heme oxygenase activity drives metabolic, inflammatory, or antiviral phenotypes. This article translates its biochemical profile into reproducible enzyme, cell-based, and HBV-focused workflows while separating established evidence from practical assay recommendations.

• Chuanxiong Cortex and Pith in CHD: Metabolomic Insights

  2026-09-09

  Li and colleagues compared the volatile chemistry and predicted pharmacology of Ligusticum chuanxiong cortex and pith using SPME-GC×GC-MS, network pharmacology, pathway analysis, and molecular docking. The study shows that anatomically distinct rhizome regions contain different candidate bioactive profiles, providing a more resolved framework for interpreting Chuanxiong in coronary heart disease research.

• Open-Platform DLP for 96-Well Hydrogel Printing

  2026-09-09

  The reference study introduces an open-platform digital light printer that produces spatially defined two-dimensional hydrogels and activates surface-bound biomolecules in a 96-well format. Its programmable LabVIEW control, planar correction, wavelength flexibility, and vessel compatibility address reproducibility and customization challenges in high-throughput biomaterials workflows.

• Intraperitoneal CAR-Macrophage Programming via mRNA-LNP

  2026-09-09

  Gu and colleagues developed a macrophage-targeted mRNA lipid nanoparticle platform to compare 36 CAR designs directly in the peritoneal environment. Their lead CD3ζ–TLR4 intracellular-domain configuration promoted inflammatory macrophage activity, remodeled the tumor microenvironment, increased TCF1+PD-1+ progenitor-exhausted CD8+ T cells, and enhanced responses to PD-1/L1 therapy.

• Machine Learning Prediction of mRNA Vaccine LNPs

  2026-09-08

  Wang and colleagues developed a LightGBM model to predict lipid nanoparticle formulations for mRNA vaccines from 325 formulation–IgG titer records. The study combined machine learning, mouse validation of DLin-MC3-DMA versus SM-102, and molecular dynamics to connect formulation variables with vaccine performance and provide a basis for virtual LNP screening.

• Reserpine (N1867): Practical Lab Workflow Guide

  2026-09-07

  Reserpine (N1867) is a high-purity research reagent for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology research. This guide covers identity verification, DMSO preparation, storage, and quality-control practices; it is not intended for diagnostic, therapeutic, clinical, or veterinary use.

• Berberine Hydrochloride: Assay Logic for Gut–Bone Research

  2026-09-07

  Berberine hydrochloride connects AMPK, epithelial biology, microbiota, and osteoimmune readouts. This article provides a salt-aware, causality-focused framework for integrating metabolic and gut–bone assays without overstating preclinical evidence.

• Sequencing Therapies in Waldenström Macroglobulinemia

  2026-09-04

  The 2021 reference article presents a genotype-informed framework for sequencing Waldenström macroglobulinemia therapy, emphasizing MYD88 and CXCR4 status alongside clinical presentation, comorbidities, and patient preferences. Its main practical contribution is to connect molecular subgroups with the relative roles of ibrutinib, chemoimmunotherapy, proteasome inhibitors, transplantation, and emerging clinical-trial agents.

8448 records 1/564 page Next 12345 下5页 Last page